Clinical Trial Update: A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects [Phase 1]

View source ↗

Summary

A Phase 1 study assessed the safety, tolerability, and pharmacokinetics of GS-6615 in healthy subjects and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemic Heart Disease

Drugs mentioned

• GS-6615

Snippet

Sponsor: Gilead Sciences | Conditions: Ischemic Heart Disease | Phase 1 | Status: COMPLETED